|
US5208036A
(en)
|
1985-01-07 |
1993-05-04 |
Syntex (U.S.A.) Inc. |
N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
US5143854A
(en)
|
1989-06-07 |
1992-09-01 |
Affymax Technologies N.V. |
Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
|
|
US5279833A
(en)
|
1990-04-04 |
1994-01-18 |
Yale University |
Liposomal transfection of nucleic acids into animal cells
|
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
|
US5283185A
(en)
|
1991-08-28 |
1994-02-01 |
University Of Tennessee Research Corporation |
Method for delivering nucleic acids into cells
|
|
US5412087A
(en)
|
1992-04-24 |
1995-05-02 |
Affymax Technologies N.V. |
Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
|
|
US5753613A
(en)
|
1994-09-30 |
1998-05-19 |
Inex Pharmaceuticals Corporation |
Compositions for the introduction of polyanionic materials into cells
|
|
ATE219660T1
(de)
|
1994-09-30 |
2002-07-15 |
Inex Pharmaceuticals Corp |
Mittel zum einbringen polyanionischer materialien in zellen
|
|
ATE544776T1
(de)
|
1994-12-29 |
2012-02-15 |
Massachusetts Inst Technology |
Chimäre dna-bindeproteine
|
|
US5695937A
(en)
|
1995-09-12 |
1997-12-09 |
The Johns Hopkins University School Of Medicine |
Method for serial analysis of gene expression
|
|
US7368551B2
(en)
|
1998-06-25 |
2008-05-06 |
The General Hospital Corporation |
De novo DNA cytosine methyltransferase genes, polypeptides and uses thereof
|
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
EP1276859B1
(en)
|
2000-04-28 |
2007-02-07 |
Sangamo Biosciences Inc. |
Targeted modification of chromatin structure
|
|
US6919204B2
(en)
|
2000-09-29 |
2005-07-19 |
Sangamo Biosciences, Inc. |
Modulation of gene expression using localization domains
|
|
WO2002057294A2
(en)
|
2001-01-22 |
2002-07-25 |
Sangamo Biosciences, Inc. |
Zinc finger proteins for dna binding and gene regulation in plants
|
|
CA2461290C
(en)
|
2001-09-24 |
2014-11-25 |
Sangamo Biosciences, Inc. |
Modulation of stem cells using zinc finger proteins
|
|
WO2003072788A1
(en)
|
2002-02-21 |
2003-09-04 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for reversibly controlling expression of target genes in cells
|
|
WO2005028630A2
(en)
|
2003-09-19 |
2005-03-31 |
Sangamo Biosciences, Inc. |
Engineered zinc finger proteins for regulation of gene expression
|
|
US20070192880A1
(en)
|
2003-10-03 |
2007-08-16 |
University Of Rochester |
Horming response element binding transregulators
|
|
US7745651B2
(en)
|
2004-06-07 |
2010-06-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use
|
|
JP5042863B2
(ja)
|
2005-02-14 |
2012-10-03 |
サーナ・セラピューティクス・インコーポレイテッド |
生物学的に活性な分子をデリバリーするための脂質ナノ粒子系組成物および方法
|
|
WO2009086558A1
(en)
|
2008-01-02 |
2009-07-09 |
Tekmira Pharmaceuticals Corporation |
Improved compositions and methods for the delivery of nucleic acids
|
|
AU2009238175C1
(en)
|
2008-04-15 |
2023-11-30 |
Arbutus Biopharma Corporation |
Novel lipid formulations for nucleic acid delivery
|
|
US20120207744A1
(en)
|
2009-03-19 |
2012-08-16 |
Mendlein John D |
Reprogramming compositions and methods of using the same
|
|
US20110071208A1
(en)
|
2009-06-05 |
2011-03-24 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated dicer-substrate interfering rna
|
|
ES2613498T3
(es)
|
2009-07-01 |
2017-05-24 |
Protiva Biotherapeutics Inc. |
Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
|
|
US8450107B1
(en)
|
2011-11-30 |
2013-05-28 |
The Broad Institute Inc. |
Nucleotide-specific recognition sequences for designer TAL effectors
|
|
EP3241902B1
(en)
*
|
2012-05-25 |
2018-02-28 |
The Regents of The University of California |
Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
|
|
WO2014093718A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
|
US20140271550A1
(en)
|
2013-03-14 |
2014-09-18 |
The Trustees Of The University Of Pennsylvania |
Constructs and Methods for Delivering Molecules via Viral Vectors with Blunted Innate Immune Responses
|
|
EP3004370B1
(en)
|
2013-06-05 |
2024-08-21 |
Duke University |
Rna-guided gene editing and gene regulation
|
|
AU2014346559B2
(en)
|
2013-11-07 |
2020-07-09 |
Editas Medicine,Inc. |
CRISPR-related methods and compositions with governing gRNAs
|
|
WO2015138870A2
(en)
|
2014-03-13 |
2015-09-17 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeted epigenetic modification
|
|
SMT202200502T1
(it)
|
2014-06-25 |
2023-01-13 |
Acuitas Therapeutics Inc |
Nuovi lipidi e formulazioni di nanoparticelle lipidiche per l'erogazione di acidi nucleici
|
|
GB201418965D0
(https=)
|
2014-10-24 |
2014-12-10 |
Ospedale San Raffaele And Fond Telethon |
|
|
US11219634B2
(en)
|
2015-01-21 |
2022-01-11 |
Genevant Sciences Gmbh |
Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
|
|
US11674144B2
(en)
|
2015-04-16 |
2023-06-13 |
California Institute Of Technology |
Fractional regulation of transcription
|
|
TWI813532B
(zh)
|
2015-06-18 |
2023-09-01 |
美商博得學院股份有限公司 |
降低脱靶效應的ｃｒｉｓｐｒ酶突變
|
|
LT3313829T
(lt)
|
2015-06-29 |
2024-08-12 |
Acuitas Therapeutics Inc. |
Lipidai ir lipidų nanodalelių sudėtys, skirtos nukleorūgščių tiekimui
|
|
WO2017068077A1
(en)
|
2015-10-20 |
2017-04-27 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Methods and products for genetic engineering
|
|
IL307179A
(en)
|
2015-10-28 |
2023-11-01 |
Acuitas Therapeutics Inc |
Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
WO2017083722A1
(en)
|
2015-11-11 |
2017-05-18 |
Greenberg Kenneth P |
Crispr compositions and methods of using the same for gene therapy
|
|
US20190127713A1
(en)
|
2016-04-13 |
2019-05-02 |
Duke University |
Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
|
|
WO2017212008A1
(en)
|
2016-06-09 |
2017-12-14 |
Curevac Ag |
Hybrid carriers for nucleic acid cargo
|
|
WO2017212007A1
(en)
|
2016-06-09 |
2017-12-14 |
Curevac Ag |
Cationic carriers for nucleic acid delivery
|
|
US10017760B2
(en)
|
2016-06-24 |
2018-07-10 |
Inscripta, Inc. |
Methods for generating barcoded combinatorial libraries
|
|
JP7308143B2
(ja)
|
2016-08-19 |
2023-07-13 |
ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ |
Ｄｎａメチル化の編集方法
|
|
JP7682604B2
(ja)
|
2016-09-07 |
2025-05-26 |
フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド |
遺伝子発現をモジュレートするための方法および組成物
|
|
CA3038960A1
(en)
*
|
2016-09-30 |
2018-04-05 |
The Regents Of The University Of California |
Rna-guided nucleic acid modifying enzymes and methods of use thereof
|
|
WO2018111944A1
(en)
|
2016-12-12 |
2018-06-21 |
Whitehead Institute For Biomedical Research |
Regulation of transcription through ctcf loop anchors
|
|
US11591621B2
(en)
|
2017-02-07 |
2023-02-28 |
Modalis Therapeutics Corporation |
Method of treating diseases associated with elevated KRAS expression using CRISPR-GNDM system
|
|
WO2018195555A1
(en)
|
2017-04-21 |
2018-10-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Crispr/cas 9-mediated integration of polynucleotides by sequential homologous recombination of aav donor vectors
|
|
US20230340471A1
(en)
|
2017-04-23 |
2023-10-26 |
Ospedale San Raffaele S.R.L. |
Permanent Epigenetic Gene Silencing
|
|
US11439692B2
(en)
|
2017-05-17 |
2022-09-13 |
Modalis Therapeutics Corporation |
Method of treating diseases associated with MYD88 pathways using CRISPR-GNDM system
|
|
US11072782B2
(en)
|
2017-07-24 |
2021-07-27 |
Albert-Ludwigs-Universitaet Freiburg |
Construct for epigenetic modification and its use in the silencing of genes
|
|
US20190233805A1
(en)
|
2017-10-04 |
2019-08-01 |
The Regents Of The University Of California |
Targetable proteins for epigenetic modification and methods for use thereof
|
|
US11629342B2
(en)
|
2017-10-17 |
2023-04-18 |
President And Fellows Of Harvard College |
Cas9-based transcription modulation systems
|
|
CA3079727A1
(en)
|
2017-10-24 |
2019-05-02 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of rare diseases
|
|
US20210047653A1
(en)
|
2018-01-30 |
2021-02-18 |
The University Of Memphis Research Foundation |
Compositions and methods for regulating a biological process
|
|
JP7555822B2
(ja)
|
2018-04-19 |
2024-09-25 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
ゲノム編集のための組成物および方法
|
|
WO2020023529A1
(en)
|
2018-07-24 |
2020-01-30 |
The Regents Of The University Of California |
Rna-guided nucleic acid modifying enzymes and methods of use thereof
|
|
US12275964B2
(en)
|
2018-08-22 |
2025-04-15 |
The Regents Of The University Of California |
Variant type V CRISPR/Cas effector polypeptides and methods of use thereof
|
|
CN113286620A
(zh)
|
2018-08-24 |
2021-08-20 |
莱兰斯坦福初级大学评议会 |
用于多核苷酸空间组织的系统和方法
|
|
CA3115158A1
(en)
|
2018-10-02 |
2020-04-09 |
Sangamo Therapeutics, Inc. |
Engineered genetic modulators
|
|
MX2021012836A
(es)
|
2019-04-23 |
2021-12-10 |
Sangamo Therapeutics Inc |
Moduladores de la expresion del gen del marco de lectura abierto 72 del cromosoma 9 y usos de los mismos.
|
|
CA3138576A1
(en)
|
2019-05-16 |
2020-11-19 |
Trustees Of Boston University |
Regulated synthetic gene expression systems
|
|
CA3135271A1
(en)
|
2019-05-28 |
2020-12-03 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting dmpk gene
|
|
WO2020247883A2
(en)
|
2019-06-07 |
2020-12-10 |
Scribe Therapeutics Inc. |
Deep mutational evolution of biomolecules
|
|
PH12021553076A1
(en)
|
2019-06-07 |
2023-08-14 |
Scribe Therapeutics Inc |
Engineered casx systems
|
|
EP4010004A4
(en)
|
2019-08-07 |
2023-09-13 |
Altius Institute For Biomedical Sciences |
Compositions and methods for modulation of gene expression
|
|
AU2020352931A1
(en)
|
2019-09-23 |
2022-03-31 |
Flagship Pioneering Innovations V, Inc. |
Modulating genomic complexes
|
|
US20220343485A1
(en)
|
2019-10-02 |
2022-10-27 |
Nippon Telegraph And Telephone Corporation |
Video quality estimation apparatus, video quality estimation method and program
|
|
US20230036273A1
(en)
|
2019-11-27 |
2023-02-02 |
The General Hospital Corporation |
System and method for activating gene expression
|
|
AU2020398658A1
(en)
*
|
2019-12-06 |
2022-07-07 |
Scribe Therapeutics Inc. |
Particle delivery systems
|
|
CA3176046A1
(en)
|
2020-05-04 |
2021-11-11 |
Michael C. BASSIK |
Compositions, systems, and methods for the generation, identification, and characterization of effector domains for activating and silencing gene expression
|
|
IL298434A
(en)
|
2020-06-02 |
2023-01-01 |
Univ California |
Gene editing compositions and methods
|
|
AU2021325586A1
(en)
|
2020-08-14 |
2023-03-23 |
The Governing Council Of The University Of Toronto |
KRAB fusion repressors and methods and compositions for repressing gene expression
|
|
CA3192654A1
(en)
|
2020-09-01 |
2022-03-10 |
The Board Of Trustees Of The Leland Stanford Junior Unversity |
Synthetic miniature crispr-cas (casmini) system for eukaryotic genome engineering
|
|
WO2022047624A1
(en)
|
2020-09-01 |
2022-03-10 |
Huigene Therapeutics Co., Ltd |
Small cas proteins and uses thereof
|
|
US20240026352A1
(en)
|
2020-11-13 |
2024-01-25 |
Duke University |
Targeted gene regulation of human immune cells with crispr-cas systems
|
|
AR124143A1
(es)
|
2020-11-25 |
2023-02-15 |
Astellas Pharma Inc |
Método para tratar la distrofia muscular mediante el direccionamiento al gen dmpk
|
|
WO2022119957A1
(en)
|
2020-12-02 |
2022-06-09 |
The Regents Of The University Of California |
Crispr-cas effector polypeptides and methods of use thereof
|
|
AU2021392719B2
(en)
|
2020-12-03 |
2025-08-14 |
Scribe Therapeutics Inc. |
Engineered class 2 type v crispr systems
|
|
EP4259791A1
(en)
|
2020-12-09 |
2023-10-18 |
Scribe Therapeutics Inc. |
Aav vectors for gene editing
|
|
CA3202977A1
(en)
|
2020-12-22 |
2022-06-30 |
Chroma Medicine, Inc. |
Compositions and methods for epigenetic editing
|
|
KR20230152689A
(ko)
|
2021-02-01 |
2023-11-03 |
엡실렌 바이오 에스.알.엘. |
유전자 침묵
|
|
WO2022261150A2
(en)
|
2021-06-09 |
2022-12-15 |
Scribe Therapeutics Inc. |
Particle delivery systems
|
|
WO2023004338A2
(en)
|
2021-07-20 |
2023-01-26 |
Epicrispr Biotechnologies, Inc. |
Systems and methods for regulating target genes
|
|
WO2023023553A2
(en)
|
2021-08-17 |
2023-02-23 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions, systems, and methods for activating and silencing gene expression
|
|
MX2024003007A
(es)
|
2021-09-08 |
2024-03-25 |
Metagenomi Inc |
Sistemas crispr de clase ii, tipo v.
|
|
JP2024534523A
(ja)
|
2021-09-21 |
2024-09-20 |
スクライブ・セラピューティクス・インコーポレイテッド |
操作されたｃａｓｘリプレッサー系
|
|
IL311611A
(en)
|
2021-09-23 |
2024-05-01 |
Scribe Therapeutics Inc |
Self-inactivating gene-editing vectors
|
|
WO2023055893A1
(en)
|
2021-09-30 |
2023-04-06 |
Peter Biotherapeutics, Inc. |
Gene regulation
|
|
EP4437092A1
(en)
|
2021-11-26 |
2024-10-02 |
Epigenic Therapeutics Inc. |
Method of modulating pcsk9 and uses thereof
|
|
CN116497002A
(zh)
|
2022-01-19 |
2023-07-28 |
中国科学院动物研究所 |
工程化的CasX核酸酶、效应蛋白及其用途
|
|
TW202346588A
(zh)
|
2022-03-04 |
2023-12-01 |
大陸商益杰立科（上海）生物科技有限公司 |
基因組編輯的組成物和方法
|
|
US20250388885A1
(en)
|
2022-03-11 |
2025-12-25 |
Epicrispr Biotechnologies, Inc. |
Compositions, systems, and methods for treating familial hypercholesterolemia by targeting pcsk9
|
|
EP4493700A2
(en)
|
2022-03-17 |
2025-01-22 |
The Board of Trustees of the Leland Stanford Junior University |
Compositions and methods for modulating alpha-synuclein expression
|
|
EP4519293A1
(en)
|
2022-05-01 |
2025-03-12 |
Chroma Medicine, Inc. |
Compositions and methods for epigenetic regulation of pcsk9 expression
|
|
WO2023235818A2
(en)
|
2022-06-02 |
2023-12-07 |
Scribe Therapeutics Inc. |
Engineered class 2 type v crispr systems
|
|
WO2023240076A1
(en)
|
2022-06-07 |
2023-12-14 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of pcsk9
|
|
CN114921439B
(zh)
|
2022-06-16 |
2024-04-26 |
尧唐(上海)生物科技有限公司 |
CRISPR-Cas效应子蛋白、其基因编辑系统及应用
|
|
CA3259638A1
(en)
|
2022-06-23 |
2023-12-28 |
Nchroma Bio, Inc. |
EPIGENETIC COMPOSITIONS AND EDITING PROCESSES
|
|
WO2023250148A1
(en)
|
2022-06-23 |
2023-12-28 |
Chroma Medicine, Inc. |
Compositions and methods for epigenetic editing
|
|
CA3260110A1
(en)
|
2022-06-24 |
2023-12-28 |
European Molecular Biology Laboratory |
MODULAR TOOL BASED ON CRISPR FOR THE SPECIFIC INTRODUCTION OF EPIGENETIC MODIFICATIONS ON TARGET LOCI
|
|
IL317874A
(en)
|
2022-06-24 |
2025-02-01 |
Tune Therapeutics Inc |
Compounds, systems and methods for reducing low density lipoproteins through targeted gene suppression
|
|
WO2024032681A1
(zh)
|
2022-08-11 |
2024-02-15 |
益杰立科(上海)生物科技有限公司 |
一种表观编辑靶点的方法及用途
|
|
KR20250128349A
(ko)
|
2022-12-23 |
2025-08-27 |
에피제닉 테라퓨틱스 피티이 리미티드 |
융합체 및 이의 용도
|
|
TW202444910A
(zh)
|
2023-03-29 |
2024-11-16 |
美商斯奎柏治療公司 |
編碼casx之信使rna
|
|
TW202444906A
(zh)
|
2023-03-29 |
2024-11-16 |
美商斯奎柏治療公司 |
用於靶向pcsk9之組合物及方法
|
|
WO2024206565A1
(en)
|
2023-03-29 |
2024-10-03 |
Scribe Therapeutics Inc. |
Repressor fusion protein systems
|